The Sulfasalazine Market is estimated to be valued at US$ 2.01 Bn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Sulfasalazine is an antibiotic and anti-inflammatory drug used for the treatment of ulcerative colitis and rheumatoid arthritis. It works by blocking the production of substances that cause inflammation and pain. Sulfasalazine is available in tablet and liquid form and is usually taken twice a day with food to reduce side effects like nausea, vomiting, and stomach pain. It may take 4-8 weeks to see maximum therapeutic benefits. Common side effects include headache, loss of appetite, vomiting, and skin rashes.
Market Dynamics:
The growth of the Sulfasalazine Market Size is driven by the increasing prevalence of ulcerative colitis and rheumatoid arthritis globally. According to the Global Burden of Disease Study in 2017, approximately 4.9 million new cases of ulcerative colitis are reported worldwide every year. Similarly, rheumatoid arthritis affects nearly 1% of the global population and is more common in women than men. The rising geriatric population also contributes to market growth as older adults are more susceptible to chronic inflammatory conditions. Additionally, ongoing research and development activities to develop advanced formulations with reduced side effects are fueling the market expansion. However, alternative biological treatment options and stringent regulations for drug approval restrain the market to a certain extent.
The Sulfasalazine Market is estimated to be valued at US$ 2.01 Bn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. The growth of the market is driven by the increasing prevalence of ulcerative colitis and rheumatoid arthritis globally. According to the Global Burden of Disease Study in 2017, approximately 4.9 million new cases of ulcerative colitis are reported worldwide every year. Similarly, rheumatoid arthritis affects nearly 1% of the global population and is more common in women than men.
Segment Analysis
The global sulfasalazine market is dominated by the rheumatoid arthritis segment which holds around 60% of the total market share. Sulfasalazine is one of the preferred drugs for treating rheumatoid arthritis as it suppresses the inflammatory responses and slows disease progression. It inhibits the transport of amino acids into leucocytes, thereby reducing inflammation.
PEST Analysis
Political: Regulation policies by authorities like FDA influence the development and approval process of drugs. For example, in 2022, FDA approved sulfasalazine extended-release tablets to treat pediatric patients with ulcerative colitis.
Economic: Growing healthcare expenditure worldwide and increasing prevalence of autoimmune diseases are driving the overall market growth. However, presence of alternative treatment options poses a challenge.
Social: Rising awareness about better management of inflammatory bowel diseases and arthritis is boosting the demand. People are preferring sulfasalazine due to its effectiveness and affordability.
Technological: Continuous R&D is helping manufacturers develop new drug formulations like extended-release tablets for improved efficacy and compliance.
Key Takeaways
The global sulfasalazine market size was valued at US$ 2.01 Bn in 2023 and is expected to reach US$ 3.12 Bn by 2030, expanding at a CAGR of 5.7% during the forecast period.
The North America region dominates the market and holds around 40% of the total share majorly due to the rising prevalence of rheumatoid arthritis in countries like US and Canada. According to Arthritis Foundation, around 54 million adults suffer from arthritis in the US.
Some of the key players operating in the sulfasalazine market are Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited. These players are focusing on new product launches and expansion of manufacturing facilities globally to strengthen their market position. For instance, in 2022, Dr. Reddy’s launched Sulfasalazine tablets in the US market as generic version of Azulfidine tablets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
